Literature DB >> 31605274

The rate of myocardial perfusion recovery after steroid therapy and its implication for cardiac events in cardiac sarcoidosis and primarily preserved left ventricular ejection fraction.

Kazuhiro Koyanagawa1, Masanao Naya2, Tadao Aikawa1, Osamu Manabe3, Sho Furuya3, Masato Kuzume1, Noriko Oyama-Manabe3, Hiroshi Ohira4, Ichizo Tsujino4, Toshihisa Anzai1.   

Abstract

BACKGROUND: Sarcoidosis is a multisystemic disorder of unknown cause characterized by immune granuloma formation in the involved organs. Few studies have reported on the myocardial perfusion changes by immunosuppression therapy in cardiac sarcoidosis (CS). Additionally, the relationship between myocardial perfusion changes and prognosis is unknown. Therefore, this study aimed to clarify myocardial perfusion recovery after steroid therapy and its prognostic value for major adverse cardiac events (MACE) in patients with CS. METHODS AND
RESULTS: Thirty-eight consecutive patients with CS {median age, 63 [interquartile range (IQR) 51-68] years; 10 men} underwent both 18F-fluorodeoxyglucose positron emission tomography/computed tomography (CT) and electrocardiography-gated single-photon emission CT (SPECT) pre- and post-steroid therapy. Patients with improved or preserved myocardial perfusion after post-therapy were defined as the recovery group and those with worsened myocardial perfusion as the non-recovery group. Twenty-six patients (68%) were categorized as the recovery group. MACE occurred in eight patients. The Kaplan-Meier curves revealed a significantly higher rate of MACE in the non-recovery group (17.4%/y vs 2.9%/y, P = 0.007).
CONCLUSIONS: Myocardial perfusion was recovered by steroid therapy in 61% and preserved in 8% of patients. Myocardial perfusion recovery after steroid therapy was significantly associated with a low incidence of MACE.
© 2019. American Society of Nuclear Cardiology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31605274     DOI: 10.1007/s12350-019-01916-4

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  3 in total

1.  Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis.

Authors:  Wataru Okumura; Tsutomu Iwasaki; Takuji Toyama; Tatsuya Iso; Masashi Arai; Noboru Oriuchi; Keigo Endo; Tomoyuki Yokoyama; Tadashi Suzuki; Masahiko Kurabayashi
Journal:  J Nucl Med       Date:  2004-12       Impact factor: 10.057

2.  18F-FMISO PET/CT detects hypoxic lesions of cardiac and extra-cardiac involvement in patients with sarcoidosis.

Authors:  Sho Furuya; Masanao Naya; Osamu Manabe; Kenji Hirata; Hiroshi Ohira; Tadao Aikawa; Kazuhiro Koyanagawa; Keiichi Magota; Ichizo Tsujino; Toshihisa Anzai; Yuji Kuge; Noriko Oyama-Manabe; Kohsuke Kudo; Tohru Shiga; Nagara Tamaki
Journal:  J Nucl Cardiol       Date:  2019-12-09       Impact factor: 5.952

3.  What does diagnostic threshold mean? Deterministic and probabilistic considerations.

Authors:  Kenichi Nakajima; Koichi Okuda; Junji Komatsu
Journal:  J Nucl Cardiol       Date:  2019-09-23       Impact factor: 5.952

  3 in total
  2 in total

1.  Corticosteroid and Immunosuppressant Therapy for Cardiac Sarcoidosis: A Systematic Review.

Authors:  Siavosh Fazelpour; Mouhannad M Sadek; Pablo B Nery; Rob S Beanlands; Niko Tzemos; Mustafa Toma; David H Birnie
Journal:  J Am Heart Assoc       Date:  2021-09-02       Impact factor: 5.501

Review 2.  Cardiac Sarcoidosis: When and How to Treat Inflammation.

Authors:  Gerard T Giblin; Laura Murphy; Garrick C Stewart; Akshay S Desai; Marcelo F Di Carli; Ron Blankstein; Michael M Givertz; Usha B Tedrow; William H Sauer; Gary M Hunninghake; Paul F Dellaripa; Sanjay Divakaran; Neal K Lakdawala
Journal:  Card Fail Rev       Date:  2021-11-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.